Read more about the article First-Line Consolidation With Cemacabtagene Ansegedleucel (Cema-Cel) in Patients With Large B-Cell Lymphoma and Minimal Residual Disease After Response to Standard Therapy: The Pivotal, Randomized, Open-Label Phase 2 ALPHA3 Study

First-Line Consolidation With Cemacabtagene Ansegedleucel (Cema-Cel) in Patients With Large B-Cell Lymphoma and Minimal Residual Disease After Response to Standard Therapy: The Pivotal, Randomized, Open-Label Phase 2 ALPHA3 Study

Continue ReadingFirst-Line Consolidation With Cemacabtagene Ansegedleucel (Cema-Cel) in Patients With Large B-Cell Lymphoma and Minimal Residual Disease After Response to Standard Therapy: The Pivotal, Randomized, Open-Label Phase 2 ALPHA3 Study
Read more about the article Please join us for an update on our AlloCAR TTM platform during a virtual CD19 Forum on Wednesday, May 19 at 2:30 p.m. PT / 5:30 p.m. ET. Registration details are available on the investor section of our website. $ALLO

Please join us for an update on our AlloCAR TTM platform during a virtual CD19 Forum on Wednesday, May 19 at 2:30 p.m. PT / 5:30 p.m. ET. Registration details are available on the investor section of our website. $ALLO

Please join us for an update on our AlloCAR TTM platform during a virtual CD19 Forum on Wednesday, May 19 at 2:30 p.m. PT / 5:30 p.m. ET. Registration details…

Continue ReadingPlease join us for an update on our AlloCAR TTM platform during a virtual CD19 Forum on Wednesday, May 19 at 2:30 p.m. PT / 5:30 p.m. ET. Registration details are available on the investor section of our website. $ALLO